Novel Technology Commercialization

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform